Kari Furtek
Clinical Assistant Professor
Department: Department of Pharmacy Practice
Department 2: School of Pharmacy
Office: 140 The Fenway, R220
 
Résumé/CV

Phone: 617-373-7460
Fax: 617-373-7655
Email: k.furtek@neu.edu

 
 

Education/degrees:      Pharm.D., University of the Pacific
                                        Post-Doctoral Training: VA Medical Center San Diego
                                        Pharmacy Practice Residency
                                        Infectious Diseases Specialty Residency

 Certification:             Board Certified Pharmacotherapy Specialist
 

Specializations:          HIV

Research Interests:    HIV, Medication Adherence,Co-morbidities associated with chronic HIV infection

Publications:   
 Furtek KJ,Best M, Schweiger T, Wilkinson J, Petrelli H.  Comparative Efficacy of Conventional Teaching Methods With and Without an Active Learning Exercise in Teaching Doctor of Pharmacy Students Medication Adherence Counseling Skills.  ACCP Poster to be presented October 2009.

Furtek KJ,Martin JA, Crum-Cianflone NF, Burgi AA, Pope BM, Hale BR. Antidepressant and Antiretroviral Medication Adherence Affects Virologic Response in HIV-Infected Patients With Comorbid Mood Disorders.  Presented at 44th Infectious Disease Society of America Meeting, Toronto, Canada, October 12-15, 2006.

 Furtek K,  Crum-Cianflone N, Bavaro M, Truett A, Chun H, Utz G, Hale BR.  The Immunologic and Virologic Success of Lamivudine and Emtricitabine in Treatment-Experienced Patients with the M184V Mutation:  Are Three Active Agents Really Necessary?  Presented at the XVI International AIDS Conference, Toronto, Canada, August 13-18, 2006.

 Ganesan A., Mccarthy S., Furtek K., Crum N., Petersen K., Decker C., Qin J., Mckaig R., Tasker S.  Comparison of the Changes in high density cholesterol (HDL) among Efavirenz (EFV) and Atazanavir (TAZ) users and characterization of factors associated with this change.  Presented at the XIV International AIDS Conference, Toronto, Canada, August 13-18, 2006.

 Crum-Cianflone N., Medina S., Brandt C., Pope B.,Furtek K., Ganesan A., Bavaro M., Utz G., Truett A., Chun H., Hale B.  High Rates of Tenofovir-related Renal Dysfunction: Associations with Low CD4 Nadir, Diabetes and Tipranavir/Ritonavir.  Presented at the the XIV International AIDS Conference, Toronto, Canada, August 13-18, 2006.

 Furtek KJ, Crum NF, Olson PE, Wallace MR.  Proton Pump Inhibitor Therapy In Atazanavir-treated Patients:  Contraindicated?  J Acquir Immune Defic Syndr 2006 Mar; 41:394-6

 Crum-Cianflone N, Hale B, Bavaro M, Truett A, MedinaS, Brandt C, Pope B,  Furtek K, Olson P, Wallace M.  Erectile Dysfunction Among HIV-infected Men.  Presented at the 13th Conference on Retroviruses and Opportunistic Infections, Denver, Colorado, February 5-8, 2006.

Wallace MR, Furtek K,Olson P, Crum N, Bavaro M, Hale B, Lim M.  Atazanavir and Proton Pump Inhibitors:  Contraindiacated?  Presented at 43rd Infectious Disease Society of America Meeting, San Francisco, California.  October 6-9, 2005.

 Furtek K, Crum NF, Powell T, Bavaro M, Hale B, Truett A, Wallace MR. Antiretroviral Regimen Changes Among HIV-Infected Patients in a Large Military Cohort.  Presented at 43rd Infectious Disease Society of America Meeting, San Francisco, California.  October 6-9, 2005.                      

 Crum NF, Furtek KJ,Bavaro M, Hale B, Truett A, Wallace MR.  Association of Highly Active Antiretroviral Therapy and Hypertension Among HIV-Infected Patients.  Presented at 43rd Infectious Disease Society of America Meeting, San Francisco, California.  October 6-9, 2005.
            

 Wallace MR, Olson P, Crum N, Furtek K,Bavaro M, Hale B, Lembo D, Lim M.  HIV Treatment Outcomes in a Large Military Clinic.  Presented at 43rd Infectious Disease Society of America Meeting, San Francisco, California.  October 6-9, 2005.

Petersen K,  Riddle MS, Jones LE, Furtek K, Christensen AR, Tasker SA, and Hale BR.  Use of Bilirubin as a Marker of Adherence to Atazanavir-based Antiretroviral Therapy.  AIDS 2005;19:1700-02.

 Furtek KJ, Crum NF, Powell TL, Hale BR, Bavaro MF, Truett AA, and Wallace MR.  Immunologic and Virologic Responses With Combination Didanosine/Tenofovir Compared to Other Nucleoside Regimens.  Presented at Third International AIDS Society Conference, Rio de Janeiro, Brazil.  July 24-27, 2005.

 Crum NF, Furtek K, Bavaro M, Hale B, Truett A, and Wallace MR. Thyroid Disease Among HIV-Infected Patients.  Third International AIDS Society Conference, Rio de Janeiro, Brazil.  July 24-27, 2005.

 Ganesan A, Crum N, Moise M, Furtek K, Wallace M, Wegner S, Williams C, Qin J, McKaig R, and Tasker S. Improvements in Serum HDL with the use of Atazanavir Based Regimens- Observations from Two Clinic Practices.  Third International AIDS Society Conference, Rio de Janeiro, Brazil.  July 24-27, 2005.

 Crum N., Powell T., Olson P., Furtek K., Brandt C., Pope B., Bavaro M., Truett A., Hale B., Wallace M.R. Association between Cholesterol levels and Erectile Dysfunction Among HIV-infected Men.  Third International AIDS Society Conference, Rio de Janeiro, Brazil.  July 24-27, 2005.

 Crum NF, Furtek KJ, Olson PE, Amling CL, and Wallace MR.  A Review of Hypogonadism and Erectile Dysfunction Among HIV-Infected Men During the Pre- and Post-HAART Eras:  Diagnosis, Pathogenesis, and Management.  AIDS Patient Care STDS 2005;19:655-71.

 Dolder CR, Furtek K,Lacro JP, Jeste DV.  Antihypertensive Medication Adherence and Blood Pressure Control in Patients With Psychotic Disorders Compared to Persons Without Psychiatric Illness.  Psychosomatics 2005; 46:135-41.

 Johns S, Furtek K,and Looney D.  Chemotherapy of Human Immunodeficiency Virus Infection.  Curr Med Chem- Immun, Endoc & Metab Agents 2004; 4:27-47.


 
[Back to Directory]
 
Manage